G-BA projects
Since 2016, the Innovation Committee of the Federal Joint Committee (G-BA) has been funding projects that aim to test innovative approaches for statutory health insurance and gain new insights into everyday healthcare.
Skip to content
G-BA "Neue Versorgungsformen"
"Neue Versorgungsformen" within the meaning of the Innovation Fund are forms of care that go beyond the current standard care provided by statutory health insurance. Funding is provided for models that further develop cross-sectoral care and contain approaches to overcome the separation of sectors, as well as those that optimize intra-sectoral interfaces.
The following G-BA projects on "Neue Versorgungsformen" are currently being funded at the Faculty of Medicine:
- MIGRA-MD
- Structured specialist migraine care – multimodal and digital
- Speaker
- Dr. Ruth Ruscheweyh
- Institution
- Department of Neurology
- Funding
- 2025 to 2029
- Website
- Project description on the G-BA website (ger)
- Topics
- Headaches are one of the most common neurological disorders. Around five percent of people in Germany suffer from migraines on more than four days a month. This often leads to significant impairment in everyday life, reduced performance, and ultimately high costs for the healthcare system.
Source: G-BA
- EASY-PID
- AI-supported pediatric infectious disease consultation
- Speaker
- Prof. Dr. Johannes Hübner
- Institution
- Department of Pediatrics, Dr. von Hauner Children’s Hospital
- Funding
- 2026 to 2027
- Website
- Project description on the G-BA website (ger)
- Topics
- Every year, 1.27 million people worldwide die from bacterial infections that can no longer be treated due to resistant pathogens. Children are particularly at risk: one in five deaths caused by antimicrobial resistance affects children under the age of five. Antimicrobial resistance also places an enormous strain on healthcare systems. Such resistance arises because antibiotics are prescribed or used too frequently and, in some cases, inappropriately – including in pediatric and adolescent medicine.
Source: G-BA
- WELCOME
- Digital, video-supported transition to post-inpatient care for premature and full-term babies with increased nursing aftercare needs
- Speaker
- Prof. Dr. Uli Fischer
- Institution
- Department of nursing services
- Funding
- 2023 to 2026
- Website
- Project description on the G-BA website
- Topics
- In Germany, around one in ten babies is born prematurely. More than 15 percent of these premature babies are cared for in specialized clinics, usually in intensive care units. When these premature babies are allowed to leave hospital, many of them still require special care: Their parents have to monitor certain vital signs and take professional care of feeding tubes, catheters or even wounds. The risk of complications is high and families' everyday lives are often characterized by fear and uncertainty. Existing support structures such as socio-medical aftercare or midwife assistance are often inadequate, meaning that those affected often only have the option of returning to hospital.
The partners in the WELCOME project want to improve aftercare for premature babies during the transition to their own home and support families from the specialist clinic. At the heart of the new form of care is an app. Parents can use it to contact the highly specialized hospital staff they are already familiar with in video consultations and via chat. Health parameters can also be documented and exchanged via the app. In addition, parents can use the app's knowledge and exchange portal to find out about the right care for newborns and local support services or network with other affected people.
The project participants are investigating whether the digital service is suitable for reducing the frequency of complications and hospital readmissions in a study involving around 230 premature babies. The study will also examine whether the parents concerned feel confident in their home environment and build up more self-confidence. The project team is also monitoring how well the new service is implemented in everyday care and what effect it has on care costs. The project is being funded for four years with a total of around 5.8 million euros.
If successful, the aftercare service for premature babies can be expanded to include telemedical support for families. This would be a gain, not least in structurally weak regions.
Source: G-BA
G-BA Versorgungsforschung
Health services research has the task of creating a scientific basis for solutions for the design, organization and financing of the healthcare system. Health services research is understood here as the scientific investigation of the provision of health-related products and services to individuals and the population under everyday conditions.
The following G-BA projects on "Versorgungsforschung" are currently being funded at the Faculty of Medicine:
- TARGET-ADE
- Targeted prevention of hospitalisations due to adverse drug events
- Project leader
- Prof. Dr. Tobias Dreischulte
- Institution
- Institute of General Practice and Family Medicine
- Funding
- 2025 to 2028
- Website
- Project description of the GBA (ger)
- Topics
- Worldwide, approximately one in every 13 admissions to a hospital's internal medicine department is caused by adverse drug events (ADEs). These can be due to interactions and side effects when taking different medications at the same time, inappropriate medication dosages, or failure to observe restrictions on use. This can have serious consequences for those affected, such as bleeding in the digestive tract or heart failure.
Source: GBA
- SOLongCOVID
- Subjective experiences of care and objective care pathways for Long COVID
- Project leader
- Dr. Daniela Koller
- Institution
- Institute of Medical Data Processing, Biometrics and Epidemiology (IBE)
- Funding
- 2024 to 2027
- Website
- Project description of the GBA (ger)
- Topics
- Providing the best possible care for people suffering from the long-term effects of SARS-CoV-2 infection remains a challenge. At least 10% of people infected with SARS-CoV-2 still show persistent symptoms or sequelae that developed after infection, even six months after infection, regardless of the severity of COVID-19 disease. Symptoms and conditions that persist or newly develop three months after infection and cannot be explained by other causes are referred to as post-COVID syndrome or post-COVID-19 condition (PCC). PCC can occur in various organ systems, with cardiovascular, respiratory, metabolic, and neurological-psychiatric conditions being particularly noteworthy.
Source: GBA
- KIDS
- AI improves diagnostics in geriatric care
- Project leader
- Prof. Dr. Falk Schwendicke
- Institution
- Polyclinic for Tooth Preservation and Periodontology
- Funding
- 2024 to 2027
- Website
- Project description of the GBA
- Topics
- Elderly people in need of care are particularly susceptible to damage to the mucous membranes in the mouth. Around 25 percent of them suffer from so-called lesions of the oral mucosa, which can sometimes develop into malignant tumors. These lesions are a diagnostic challenge for dentists working in elderly care. Not only does the further diagnostic and treatment effort depend on their assessment, but also the associated burden for the person in need of care. However, diagnostic accuracy is often limited.
The KIDS project aims to improve the diagnosis of oral mucosal lesions in long-term inpatient care by using artificial intelligence (AI) systems to support decision-making. First, the project participants will optimize and test AI models that have already been tried and tested and check their accuracy and reliability. Based on this, software will be developed that is suitable for practical use in elderly care. In a study with residents of inpatient care facilities, we are investigating whether the AI-supported assessment of lesions provides more accurate diagnoses compared to the usual assessment by dentists. By evaluating the processes and analyzing the costs, the project will also examine whether the use of AI is applicable, acceptable and cost-effective under practical conditions. The project is being funded for three years with a total of around 1.1 million euros.
If the new software proves successful, it can support diagnostic practice in care for the elderly, allowing care processes to be better managed and the quality of life of those in need of care to be improved. The findings from the project could also be transferred to the AI-supported care of other diseases.
Source: GBA
- PARTNER
- Interprofessional treatment pathway for patient-centered deprescribing of psychotropic, sedative and anticholinergic drugs in elderly patients with multimedication
- Project leader
- Prof. Dr. Tobias Dreischulte
- Institution
- Institute of General Practice and Family Medicine
- Funding
- 2022 to 2026
- Website
- Project description of the GBA
- Topics
- If people have to take five or more medicines at the same time, this increases the risk of adverse drug reactions. According to a 2018 study by the University Hospitals of Ulm, Fürth, Bonn and Stuttgart, for example, 6.5% of all cases in emergency departments can be attributed to this. Elderly people who take drugs that have an anxiolytic, sedative, sleep-inducing and muscle-relaxing effect, such as hypnotics or opioids, over a long period of time are particularly at risk. These adverse drug effects are well known in medicine, but the continued widespread use among older people suggests that raising awareness of the issue alone is not enough.
The PARTNER project aims to help reduce the misuse and overuse of these drugs. Discontinuing the active ingredients or switching to a lower dosage (deprescribing) is often time-consuming and requires implementation support for GP practices, pharmacies and the patients themselves.
Accordingly, the project provides for a treatment pathway that includes the distribution of training materials and in-depth cooperation between GP practices and pharmacies in the form of a workshop with case conferences. In addition, patients receive a brochure on deprescribing, which they first discuss with their pharmacist. Based on this, the GP and patient make a joint decision about deprescribing. The effectiveness, costs, benefits and appropriateness of the measure are tested in two groups of 176 patients each, with the control group only receiving general information about drug risks. The project will be funded for 42 months with a total of around 2.05 million euros.
If successful, the project will show whether the adoption of the measure in standard care is effective, efficient and expedient and what the cooperation between GP practices and pharmacies should look like in order to reduce the risk of adverse drug reactions in the long term.
Source: GBA